Andy Chevign News Today : Breaking News, Live Updates & Top Stories | Vimarsana

On 20 October 2023, the Luxembourg National Research Fund (FNR) marked a significant milestone with the 15th edition of the FNR Awards. Rewarding exce....

Scientists from the Immuno-Pharmacology and Interactomics group at the Luxembourg Institute of Health (LIH), in collaboration with the Center for Drug Discovery at RTI International (RTI), have demonstrated that conolidine, a natural painkiller derived from the pinwheel flower and traditionally used in Chinese medicine, interacts with the newly identified opioid receptor ACKR3/CXCR7 that regulates opioid peptides naturally produced in the brain. The researchers also developed a synthetic analogue of conolidine, RTI-5152-12, which displays an even greater activity on the receptor.

Building on their previous findings, scientists from the Immuno-Pharmacology and Interactomics group at the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH), in collaboration with the Center for Drug Discovery at RTI International (RTI), a nonprofit research institute, have demonstrated that conolidine, a natural painkiller derived from the pinwheel flower and traditionally used in Chinese medicine, interacts with the newly identified opioid receptor ACKR3/CXCR7 that regulates opioid peptides naturally produced in the brain.

Award Celebrates Molecular Pharmacology Studies at LIH Dec 31 2020 Read 348 Times The international 2019 Galien Prize in Pharmacology has been awarded to Luxembourg Institute of Health (LIH) scientists Dr Andy Chevigné and Dr Martyna Szpakowska from the LIH Department of Infection and Immunity (DII) for their outstanding contribution to molecular pharmacology. Frank Vandenbroucke, Belgian Minister of Public Health and Social Affairs, along with representatives of pharmaceutical companies and healthcare hubs attended the virtual prize ceremony. The two LIH researchers were commended for their...

A discovery by Luxembourg Institute of Health (LIH) researchers offers hope to chronic pain patients as it paves the way for a new generation of drugs that won’t rely on the use of classical opiates.  “There is a clear medical need to treating chronic pain, because you cannot really tackle this with classical opioids without important side effects,” said Andy Chevigné, who oversees the research project. The US department of health, for example, estimates that more than 130 people a day die from opioid-related drug overdoses in the country. More than 10 million people are misusing pres...